Biogen Inc
BIIB181.940USD
-0.020-0.01%
收盤 11/26, 16:00（美東）報價延遲15分鐘
26.69B總市值
16.59本益比TTM
關於 Biogen Inc 公司
Biogen Inc. 是一家全球性生物製藥公司。該公司致力於爲全球患有嚴重和複雜疾病的人們發現、開發和提供先進的治療方法。該公司經營一系列藥物，用於治療多發性硬化症 (MS)、脊髓性肌萎縮症 (SMA)、阿爾茨海默病和肌萎縮側索硬化症 (ALS)。該公司專注於推進其在神經病學、專業免疫學和罕見疾病領域的產品線。其上市產品包括用於治療 MS 的 TECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI 和 FAMPYRA；用於治療 SMA 的 SPINRAZA；用於治療弗裏德賴希共濟失調的 SKYCLARYS；用於治療 ALS 的 QALSODY 和用於治療嚴重斑塊狀銀屑病的 FUMADERM。它還與 Eisai 合作，將 LEQEMBI 商業化，用於治療阿爾茨海默病，並與 Sage 合作，將 ZURZUVAE 商業化，用於治療產後抑鬱症 (PPD)。
Biogen Inc簡介
公司代碼BIIB
公司名稱Biogen Inc
上市日期Sep 17, 1991
CEOMr. Christopher A. (Chris) Viehbacher
員工數量7605
證券類型Ordinary Share
年結日Sep 17
公司地址225 Binney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02142
電話17814642000
網址https://www.biogen.com/
公司代碼BIIB
上市日期Sep 17, 1991
CEOMr. Christopher A. (Chris) Viehbacher
Biogen Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.42K
+39.19%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
5.77K
-8.22%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
5.47K
+76.33%
Ms. Susan Langer
Ms. Susan Langer
Independent Director
Independent Director
3.79K
+166.90%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
其他
498.00M
18.82%
地區USD
名稱
營收
佔比
United States
1.38B
52.21%
Rest of World
937.60M
35.44%
United states-Revenues from anti-CD20 therapeutic
467.30M
17.66%
Rest of World-Other revenues
244.60M
9.25%
業務
地區
業務USD
名稱
營收
佔比
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
其他
498.00M
18.82%
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
其他
64.59%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
其他
64.59%
股東類型
持股股東
佔比
Investment Advisor
52.44%
Investment Advisor/Hedge Fund
26.19%
Hedge Fund
8.03%
Pension Fund
2.94%
Research Firm
2.45%
Sovereign Wealth Fund
1.59%
Bank and Trust
1.59%
Individual Investor
0.17%
Family Office
0.15%
其他
4.45%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
2020
136.90M
93.32%
-6.47M
2025Q2
2075
135.74M
92.58%
-12.69M
2025Q1
2149
136.82M
93.38%
-11.44M
2024Q4
2130
138.58M
94.69%
-5.19M
2024Q3
2109
135.95M
93.33%
-6.54M
2024Q2
2116
135.72M
93.21%
-7.14M
2024Q1
2121
136.44M
93.87%
-5.95M
2023Q4
2151
135.61M
93.59%
-2.07M
2023Q3
2177
132.42M
91.43%
-7.53M
2023Q2
2240
133.77M
92.42%
-4.86M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
17.21M
11.74%
+255.44K
+1.51%
Jun 30, 2025
PRIMECAP Management Company
15.80M
10.78%
-141.14K
-0.89%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.19M
5.59%
-504.36K
-5.80%
Jun 30, 2025
State Street Investment Management (US)
7.47M
5.09%
+71.90K
+0.97%
Jun 30, 2025
Wellington Management Company, LLP
4.80M
3.27%
+125.98K
+2.70%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.92M
2.67%
+71.29K
+1.85%
Jun 30, 2025
Point72 Asset Management, L.P.
3.83M
2.61%
+3.42M
+840.86%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
3.00M
2.05%
-10.62K
-0.35%
Aug 31, 2025
Norges Bank Investment Management (NBIM)
2.26M
1.54%
-61.02K
-2.62%
Jun 30, 2025
Invesco Capital Management LLC
2.04M
1.39%
+32.06K
+1.59%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Invesco Biotechnology & Genome ETF
5.03%
iShares Neuroscience and Healthcare ETF
4.13%
First Trust NASDAQ Pharmaceuticals ETF
3.82%
VanEck Biotech ETF
3.33%
First Trust NYSE Arca Biotechnology Index Fund
3.24%
Invesco Pharmaceuticals ETF
2.74%
First Trust Health Care Alphadex Fund
2.36%
Global X US Cash Flow Kings 100 ETF
2.26%
ProShares Ultra Nasdaq Biotechnology
2.12%
Invesco Nasdaq Biotechnology ETF
2.08%
查看更多
Invesco Biotechnology & Genome ETF
佔比5.03%
iShares Neuroscience and Healthcare ETF
佔比4.13%
First Trust NASDAQ Pharmaceuticals ETF
佔比3.82%
VanEck Biotech ETF
佔比3.33%
First Trust NYSE Arca Biotechnology Index Fund
佔比3.24%
Invesco Pharmaceuticals ETF
佔比2.74%
First Trust Health Care Alphadex Fund
佔比2.36%
Global X US Cash Flow Kings 100 ETF
佔比2.26%
ProShares Ultra Nasdaq Biotechnology
佔比2.12%
Invesco Nasdaq Biotechnology ETF
佔比2.08%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Biogen Inc的前五大股東是誰？
Biogen Inc的前五大股東如下：
The Vanguard Group, Inc.持有股份：17.21M佔總股份比例：11.74%。
PRIMECAP Management Company持有股份：15.80M佔總股份比例：10.78%。
BlackRock Institutional Trust Company, N.A.持有股份：8.19M佔總股份比例：5.59%。
State Street Investment Management (US)持有股份：7.47M佔總股份比例：5.09%。
Wellington Management Company, LLP持有股份：4.80M佔總股份比例：3.27%。
The Vanguard Group, Inc.持有股份：17.21M佔總股份比例：11.74%。
PRIMECAP Management Company持有股份：15.80M佔總股份比例：10.78%。
BlackRock Institutional Trust Company, N.A.持有股份：8.19M佔總股份比例：5.59%。
State Street Investment Management (US)持有股份：7.47M佔總股份比例：5.09%。
Wellington Management Company, LLP持有股份：4.80M佔總股份比例：3.27%。
Biogen Inc的前三大股東類型是什麼？
Biogen Inc 的前三大股東類型分別是：
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
有多少機構持有Biogen Inc(BIIB)的股份？
截至2025Q3，共有2020家機構持有Biogen Inc的股份，合計持有的股份價值約為136.90M，占公司總股份的93.32% 。與2025Q2相比，機構持股有所增加，增幅為0.73%。
哪個業務部門對Biogen Inc的收入貢獻最大？
在FY2025Q2，MS product revenues-TYSABRI業務部門對Biogen Inc的收入貢獻最大，創收839.80M，占總收入的31.74% 。
